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INTRODUCTION
Plasminogen activator inhibitor type-1 (PAI-1) is a fast and specific inhibitor of the urokinasetype plasminogen activator (uPA) and the tissue-type plasminogen activator (tPA). PAI-1 is therefore an important regulator of the physiological and pathophysiological functions of plasminogen activation. A high level of PAI-1 in blood is associated with an increased risk of thrombotic events (for a review, see (Vaughan, 1998) ). PAI-1 is therefore a potential target for anti-thrombotic therapy.
A high level of PAI-1 in tumours is associated with a poor prognosis and several studies have suggested that PAI-1 is contributory to tumour invasion and metastasis (for reviews, see (Andreasen, 2007; Andreasen et al., 2000; Andreasen et al., 1997; Durand et al., 2004) ). PAI-1 is therefore a potential target for anti-cancer therapy.
PAI-1 belongs to the serpins, a protein family of which the best characterised members are known to be inhibitors of serine proteases. Serpins are globular proteins consisting of three β -sheets (A, B and C) and nine α -helices (A to I) ( Fig. 1 ). Of crucial importance for the inhibitory mechanism of serpins is the surface-exposed reactive center loop (RCL), tethered between β -strands 1C and 5A.
The active site of the protease attacks the P1-P1' bond in the RCL as a substrate, but at the enzymeacyl intermediate stage, where the active site serine of the protease and the P1 residue are linked by an ester bond, the N-terminal part of the RCL inserts as β -strand 4, thereby pulling the protease to the opposite pole of the serpin and distorting its active site. The energy required for this process stems from stabilization of the serpin in the relaxed conformation with an inserted RCL, as opposed to the MOL #46417
PAI-1 and antithrombin III are the only serpins known to spontaneously adopt the relaxed conformation without prior cleavage of the RCL. This transition is referred to as latency transition and involves the insertion of the N-terminal part of the intact RCL as β -strand 4A while the C-terminal part and β -strand 1C is stretched out on the surface of the molecule (for reviews, see (Andreasen, 2007; Andreasen et al., 2000; Andreasen et al., 1997; Durand et al., 2004; Huntington, 2006; Wind et al., 2002) ).
Attempts to utilise PAI-1 as a therapeutic target should be based on the knowledge of its inhibitory mechanism. There are several possible ways of inactivating the anti-proteolytic actions of PAI-1. Several well-studied examples include: Introducing a steric hindrance that blocks the initial complex formation between PAI-1 and its target proteases; an inhibition of the conformational change in PAI-1 that is associated with complex formation, resulting in cleavage of PAI-1 as a substrate; and conversion of PAI-1 to an inactive, e.g., latent form or polymerised form. Several antibodies have been described that inactivate PAI-1 by these different methods (for a review, see (Gils and Declerck, 2004) ). For instance, the monoclonal antibody MA33B8 was demonstrated to increase strongly the rate of latency transition of PAI-1. The fact that MA33B8 binds preferentially to RCL-inserted forms of PAI-1 prompted the hypothesis that antibody binding depends on a partial insertion of the RCL in active PAI-1, and that this partial insertion results in exposure of the epitope that permits binding of MA33B8 and the subsequent increase in the rate of latency transition (Verhamme et al., 1999) . The epitope for MA33B8 includes residues from the loop connecting α -helix D and β -strand 2A, from β -strand 3A, and from β -strand 2B (Gorlatova et al., 2003; Naessens et al., 2003) . Other PAI-1 inactivators include various peptides corresponding to the reactive centre loop in PAI-1 have been found to be able to insert between β-strands 3A and 5A, inhibit RCL insertion during reaction with target proteases and thus induce substrate behaviour (Eitzman et al., 1995; Xue et al., 1998) . A number of organochemical compounds were reported to inactivate the anti-proteolytic activity of PAI-1 by a variety of mechanisms (for reviews, see (Andreasen, 2007; Durand et al., 2004; Stoppelli et al., In press)). High concentrations of non-ionic detergents were found to induce substrate behaviour and then latency transition (Andreasen et al., 1999; Ehnebom et al., 1997; Gils and Declerck, 1998; MOL #46417
MATERIALS AND METHODS
PAI-1 -Human, murine, the murine-hF-human chimera, human-hF-murine PAI-1 chimera, and variants of PAI-1 carrying one or more mutations, were expressed with an N-terminal His 6 -tag and purified from E. coli cells as described previously (Dupont et al., 2006; Wind et al., 2003) . The murine-hF-human chimera consisted of the murine sequence from the N terminus to residue 122, the conserved human and murine sequence between residues 123 and 142, and the human sequence from residue 143 to the C terminus. Correspondingly, the human-hF-murine chimera consisted of the human sequence from the N terminus to residue 122, the conserved murine and human sequence between residues 123 and 142, and the murine sequence from residue 143 to the C terminus. Natural glycosylated human PAI-1 was purified in the latent form by immunoaffinity chromatography from serum-free conditioned medium of dexamethasone-treated HT-1080 cells and reactivated by denaturation with 4 M guanidinium chloride and dialysis against 10 mM Hepes, pH 7.4, 140 mM NaCl (Hepes-buffered saline, HBS) (Munch et al., 1993) . In some cases, preparations of recombinant PAI-1 with ~100% activity were generated by hydrophobic chromatography using phenyl-Sepharose and an ammonium sulfate gradient, followed by concentration on a small column of heparinSepharose . Labeling of the S340C (P9) residue of PAI-1 was performed with N-((2-(iodoacetoxy)ethyl)-N-methyl)amino-7-nitrobenz-2-oxa-1,3-diazole (IANBD ester, Molecular Probes) to create the fluorescently labelled variant, PAI-1 P9-NBD , essentially as described .
Proteases -Natural human uPA was purchased from Wakamoto Pharmaceutical Co. (Tokyo, Japan). Low molecular weight uPA (LMW-uPA), i.e., uPA N-terminally truncated at Lys136, was prepared as described (Egelund et al., 2001b) .
Antibodies -Monoclonal anti-PAI-1 antibodies were those previously described: mAb-1 Nielsen et al., 1986) ; mAb-2 (Wind et al., 2001); mAb-5 (Munch et al., 1991); mAb-6 (Wind et al., 2001); mAb-7 (Gils et al., 2003) ; MA33B8 (Gorlatova et al., 2003; Verhamme et al., 1999) ; MAH4B3 (Declerck et al., 1995; Gils et al., 2003) . A preparation of rabbit polyclonal anti-PAI-1 antibodies was that previously described (Offersen et al., 2003) . A This article has not been copyedited and formatted. The final version may differ from this version. Screening of Phage Library -Monoclonal antibodies, mAb-1 and mAb-5 (5 µg/mL in 100 mM NaHCO 3 /Na 2 CO 3 , pH 9.6), were immobilized in Immunotubes (Maxisorp, Nunc, Denmark), and unspecific binding was blocked by HBS supplemented with 5% skimmed milk powder. PAI-1, (50 nM in HBS + 20% glycerol) pre-incubated with 20 µM bis-ANS, 200 µM SDS, 50 µM XR5118 or alone, was captured in the antibody-coated tubes followed by incubation with approximately 10 11 colony forming units (c.f.u.) from each of four peptide repertoires in the formats X 7 , CX 7 C, CX 10 C, and CX 3 CX 3 CX 3 C, respectively, where X denotes random natural amino acids (Koivunen et al., 1994 preparations, and tested for binding in an ELISA with mAb-1-or mAb-5-immobilized PAI-1 (see below). The sequences of the peptides displayed on individual phage clones were determined by sequencing the encoding DNA as described previously (Wind et al., 2001 ) .
Expression of Paionin-4 Peptide Sequence Fused to the N-terminal Domains of the Phage Coat
Protein g3p -The procedure for cloning and expression of the peptide-containing fusion proteins has been described in detail previously (Hansen et al., 2005) . Briefly, a DNA fragment encoding the paionin-4 peptide fused to domain 1 and 2 (D1D2) of the minor phage coat protein g3p was amplified from the respective phage using PCR. The generated PCR products were purified and ligated into the E. coli expression vector pET20b(+) (Novagen, UK). The inserts and their flanking cloning sites were validated by sequencing and the paionin-4-D1D2 fusion protein was expressed from E. coli BL21(DE3)pLysS cells (Novagen, UK) and purified using immobilised metal affinity chromatography and size exclusion chromatography (Scott and Smith, 1990) .
DNA fragments encoding deletion mutants of the paionin-4 sequence were PCR-amplified from paionin-4 phages and ligated into a modified pET20b(+) vector, pETD1D2 (Hansen et al., 2005) . The resulting vectors allowed the expression of fusion proteins composed of truncated paionin-4 and domains 1 and 2 from the phage coat protein g3p. Expression and purification of these was performed as described above for paionin-D1D2.
ELISA for Measuring PAI-1-Paionin-4-Phage Particle Binding -Five µl supernatant from paioin-4 phage-infected E. coli cultures, incubated overnight at 37°C to propagate the phage, was mixed with 95 µl HBS supplemented with 0.25 µg PAI-1, which had been preincubated with inactivators as described, 5% skimmed milk powder and 20% glycerol and incubated for 1 h at room temperature. Formed PAI-1-phage complexes were captured on 500 ng monoclonal anti-PAI-1 antibody, mAb1 or mAb5, immobilised in wells of a 96-well Maxisorp plate (Nunc, Denmark), and detected with an HRP-conjugated monoclonal anti-M13 antibody (Amersham Pharmacia Biotech, Sweden). The ELISA was developed with a peroxidise-reaction.
ELISA for Measuring PAI-1-Paionin-3-Phage Particle Binding -E. coli PAI-1, ~100% in the active form after phenyl-Sepharose chromatography, in HBS with 0.2% BSA and in concentrations as indicated for each single experiment, was incubated for 2 min at room temperature in the absence or presence of 100 nM monoclonal antibody or at 37 ºC in the presence of 10 µ M paionin-4-D1D2 fusion protein or 10 µ M D1D2. Samples were then taken for analysis in an ELISA, in which 500 ng monoclonal anti-PAI-1 antibody mAb-6 was coated onto the wells of a 96-well Maxisorp plate (Nunc, Denmark). The PAI-1 samples were added to the wells in a concentration of 10 nM and incubated in the wells for 30 minutes at room temperature. The next layer was paionin-3 phage (CLTWPRYLC-version (Dupont et al., 2006) Fluorescence Emission Spectroscopy -Emission spectra of the binding interactions between labeled PAI-1 P9-NBD and fusion proteins or monoclonal antibodies were carried out in a SPEX-3 spectrofluorimeter equipped with a Peltier temperature controller maintaining the measurement and incubation temperatures at 25°C. Fluorescence experiments were carried out using semi-micro (0.2 x 1.0-cm) quartz cuvettes and in a reaction buffer containing 30 mM Hepes, 135 mM NaCl, 1 mM EDTA, 0.1% PEG 8000, pH 7.4. The excitation wavelength used for studying the fluorescence of PAI-1 P9-NBD was 480 nm, and the emission spectra were scanned from 500 to 650 nm using a bandwidth of 5 nm and 2.5 nm for the excitation and emission beams, respectively. Emission spectra for PAI-1 P9-NBD (50 nM) were recorded prior to and after the addition of fusion proteins or monoclonal antibodies (500 nM) and incubation at 25°C for time periods indicated for each single experiment.
Results are presented as the averaged spectra of three independent acquisitions. All individual emission spectra were collected as averages of three emission scans using a 0.5-s integration over a 1.0-nm step resolution and corrected for background fluorescence in the absence of PAI-1 P9-NBD and This article has not been copyedited and formatted. The final version may differ from this version. Analyzer with a thermo-stated syringe chamber. Excitation was at 480 nm, and a filter with a cutoff below 515 nm was used to monitor fluorescence emission. Stopped-flow experiments were carried out under pseudo-first-order conditions as has been previously described (Verhamme et al., 1999) 
Surface Plasmon Resonance Measurements of Binding -In order to determine association and dissociation rate constants and equilibrium dissociation constants for the binding between mAb-7 and different wt and mutant PAI-1 conformations (e.g., active, latent, and proteasecomplexed), the antibody was immobilised on a CM5 chip to 200 response units. The various PAI-1 variants were injected over the chip in concentrations between 0.2 and 500 nM for 60 s at a flow rate of 30 µl/min, after which time the dissociation was followed for 10 min. After each cycle, the chip was regenerated with 10 µl of a 10 mM glycine/HCl solution, pH 2.5, 0.5 M NaCl. The association rate constants, the dissociation rate constant, and the equilibrium dissociation constants were determined by analysing the kinetic data by a global fit to a 1:1 binding model with the BIACORE T100 evaluation software. lost at an about 2-fold faster rate. Paionin-4 also increased the rate of activity loss of the stable PAI-1 variant (14-1B, N152H-K156T-Q321L-M356I), which has a very slow latency transition rate (Berkenpas et al., 1995) . In contrast, the effect on W177F, which also has a slow latency transition rate (Blouse et al., 2003) , was small. There was no effect on the half-life of murine PAI-1.
Determination of PAI-1 Specific Inhibitory Activity
Importantly, vitronectin abolished the effect of paionin-4-D1D2 on the rate of latency transition (Table 1) .
We wished to confirm that the faster rate of activity loss in the presence of paionin-4-D1D2
was actually due to a faster rate of latency transition. With this aim, we used two independent assays for latency transition. First, we employed phage with the peptide sequence paionin-3, which we previously demonstrated can be used as a specific probe for latent PAI-1, because it binds to a site exposed upon extraction of β -strand 1C during latency transition (Dupont et al., 2006) . We found that during incubations at 37 o C, the binding affinity to paionin-3 phage increased with a rate indistinguishable from the rate by which activity was being lost. In four independent experiments, the half-life for the approach towards maximal paionin-3 phage binding was 56 ± 7 min without This article has not been copyedited and formatted. The final version may differ from this version. additions, 27 ± 3 min in the presence of 10 µM paionin-4-D1D2, and 49 ± 11 min in the presence of 10 µM D1D2 (Fig. 2) , values matching the half-lives for activity loss listed in Table 1 . Second, we took advantage of previous work demonstrating that the labeling of the P9 position of PAI-1 (S340C) with the environmentally sensitive fluorescent probe NBD produces a PAI-1 variant (PAI-1 P9-NBD ) in which the RCL insertion occurring during latency transition may be followed by fluorescence spectroscopy . Full insertion of the P9-NBD-labeled RCL as s4A results in a sizable fluorescence increase that is consistent with transfer of the probe from a solvent exposed to a more hydrophobic environment. Fig. 3 illustrates the fluorescence emission spectrum of the PAI-1 P9-NBD variant prior to and following incubation with or without paionin-4-D1D2 for 7 days at 25 o C. The spectrum following the extended incubation showed a several-fold enhancement in NBD fluorescence with the expected ~10-nm blue shift in peak emission from 543 nm to 533 nm, previously shown to accompany loop insertion during latency . The net fluorescence enhancement was significantly greater in the presence of paionin-4-D1D2 than in its absence. The fluorescence spectrum of PAI-1 P9-NBD in the presence of paionin-4-D1D2 corresponded to that achieved by full loop insertion (data not shown). Incubation in the absence of paionin-4-D1D2 gave an amplitude of only about half of that, corresponding to a rate constant of approximately 2 x 10 -4 min -1 . The fact that this is somewhat slower than expected from the date in Table 1 can be accounted for by the P9-MBD probe delaying loop insertion (9).
From these two lines of evidence, we concluded that the faster rate of activity loss in the presence of paionin-4-D1D2 was due to an increased rate of latency transition.
Analysis of the Binding of Paionin-4 to Different Conformational Forms of PAI-1 by Surface
Plasmon Resonance -In order to obtain a quantitative estimation of the binding of paionin-4 to PAI-1, we immobilised the paionin-4-D1D2 fusion protein on a BIACORE chip and injected different conformational forms of PAI-1 in varying concentrations. As a control, we immobilized D1D2 without a peptide fusion partner, and corrected the binding to the paionin-4-D1D2 chip for the binding to the D1D2 chip. The binding to D1D2 was always less than 1 response unit. The association and the dissociation of PAI-1 to the paionin-4-D1D2 chip occurred very fast, preventing us from determining rate constants. This particular interaction was consequently analysed under conditions yielding steady This article has not been copyedited and formatted. The final version may differ from this version. (Table   2 ). It is seen that uPA-complexed PAI-1 had a higher affinity to paionin-4-D1D2 than the preparations of active and latent PAI-1. uPA alone did not bind above background. There was a marginal difference in affinity between the preparation of latent and the preparation of active PAI-1, while the active 14-1B variant of PAI-1 had a lower affinity than active wt PAI-1. phages to PAI-1 in the presence of a variety of monoclonal anti-PAI-1 antibodies was investigated by a phage particle ELISA (Fig. 4) . In the presence of the monoclonal antibodies MA33B8 and mAb-7, the phage binding was not above background level, indicating that these antibodies competed for phage binding and that the paionin-4 binding site overlaps with the epitopes for these two antibodies.
Mapping of the Binding
Paionin-4 and heparin competed for binding to PAI-1, as revealed by a phage ELISA (data not shown).
Mapping of the binding site for paionin-4 by site-directed mutagenesis -The epitope for
MA33B8 was previously mapped to the loop connecting α -helix D and β -strand 2A, β -strand 3A, and the loop connecting β -strands 2B and 3B (Gorlatova et al., 2003; Naessens et al., 2003) . Heparin has been reported to bind in a region spanning α -helix E and α -helix D, with important residues being K82 and K90 (Ehrlich et al., 1992) . These findings and the above results suggested to us that the binding site for paionin-4 might also be in the α -helix D region of PAI-1. In order to determine the binding site for paionin-4 more precisely, we screened about 45 mutants with Ala substitutions for paionin-4 binding in phage particle ELISA, using PAI-1 in the latent form. The mutants which had an unambiguously, more than 2-fold reduced binding to paionin-4 phage in phage ELISA were then D91A, and E92A (Table 3 ). The mutated residues were therefore considered part of the paionin-4 binding site. Murine PAI-1 and two chimeras between murine and human PAI-1 also had reduced binding to paionin-4 (Table 3 ). The two chimeras were composed of the human and murine parts of PAI-1 N-and C-terminal to a conserved stretch of residues in hF.
Functional effects of mAb-7 -Based on the paionin-4-D1D2 phage ELISA, mAb-7 appears to have an epitope close to that of MA33B8 and to the binding site for paionin-4. We previously demonstrated that like MA33B8 (Verhamme et al., 1999) , mAb-7 induces a rapid irreversible loss of inhibitory activity of PAI-1 . We therefore hypothesised that mAb-7, like MA-33B8, rapidly induces conversion to the latent state. In order to compare the mechanism for latency transition of paionin-4 to that for a latency-inducing antibody, we characterised the functional effect of mAb-7
on PAI-1 and its binding epitope on PAI-1 in detail. In order to provide evidence for latency-induction by mAb-7, we used two independent assays. We first employed the paionin-3 peptide phage ELISA as described above. Clearly, both mAb-7 and MA-33B8 induced paionin-3 phage binding, while a control anti-PAI-1 antibody had no effect on the binding (Fig. 5) . Moreover, when mAb-7 was incubated with PAI-1 P9-NBD , we observed a rapid enhancement in the fluorescence emission and in the same manner as paionin-4, a ~10 nm blue shift in the emission peak that is characteristic for RCL insertion and transition to the latent conformation (Fig. 6A) . A time course of antibody-induced latency by mAb-7 is shown in Fig. 6B for 25 nM PAI-1 P9-NBD and 1.0 µN mAb-7. As was found for mAb MA33B8, the first order rate constant increased linearly up to the highest concentration of mAb-7 tested (3.3 µN). The concentration dependence of the reaction on mAb-7 (Fig 6B inset) , a rate very close to the reported rate for MA33B8 (Verhamme et al., 1999) . On the basis of these findings, we concluded that mAb-7 indeed causes a rapid conversion to the latent state in a manner analogous to MA33B8.
Next, we compared the binding of wt PAI-1 in active, latent, and uPA-complexed state to mAb-7 by the use of surface plasmon resonance, with mAb-7 coupled to a CM5 chip (Fig. 7) . Active PAI-1 wt bound at most slightly slower to a mAb-7-coated chip than latent PAI-1 wt and uPA-wt PAI-1 complex. When passing uPA over a mAb-7 chip saturated with active wt PAI-1, there was no measurable binding. of latent PAI-1 wt, but the binding of active PAI-1 W177F occurred about 5-fold slower than binding of active wt PAI-1; W177F has a considerably slower latency transition rate than wt PAI-1 (Table 1) .
But again, uPA was unable to bind to the mAb-7 coated chip saturated with PAI-1 W177F. Moreover, when the stable PAI-1 variant 14-1B, with an extremely slow latency transition, was passed over the chip in its active state, there was no measurable binding even at 250 nM (Table 5) . These results are consistent with the notion that with the time resolution possible with the BIACORE, active PAI-1 is converted to latent PAI-1 as it binds to mAb-7 on the chip.
Mapping the epitope for anti-PAI-1 mAb-7 -We next mapped the epitope for mAb-7 by the use of site-directed mutagenesis. We first measured the IC 50 values for the inactivation of wt and mutant PAI-1 by this antibody (Table 4 ). The IC 50 value for inactivation of PAI-1 by mAb-7 was found to increase more than 2-fold with the substitutions P87A, W88A, K90A, D91A, W177F, K178A, and H231A. The stable variant of PAI-1, 14-1B, also had a strongly increased IC 50 value. Murine PAI-1 and the two murine-human PAI-1 chimeras showed strongly increased IC 50 values as well. A number of residues were by the same strategy excluded from the epitope.
We next studied the binding of the substitution mutants by surface plasmon resonance. Because active PAI-1 appears to be converted to the latent form when binding to mAb-7 immobilized on a BIACORE chip (see above), the K D values for PAI-1 binding to mAb-7 could only be determined meaningfully with latent or uPA-complexed PAI-1, and we decided to test the effect of the substitution mutations by the use of latent PAI-1. For each mutant, we determined the association rate constant, the dissociation rate constant, and the K D as the ratio between the rate constants ( (Table 4 ). In addition, the stable PAI-1 variant, being used in the active state, showed no measurable binding, and murine PAI-1 and the 2 murine-human chimeras had a strongly reduced binding. The variation in the K D values was mainly due to variation in the dissociation rate constant. On the basis of these findings, we concluded that mAb-7 has an epitope This article has not been copyedited and formatted. The final version may differ from this version. 
DISCUSSION
In this report, we describe studies aimed at isolating novel types of inactivators of PAI-1, a therapeutic target in cancer and cardiovascular diseases. Previously, a variety of low molecular mass organochemicals have been found to inhibit PAI-1's anti-proteolytic activity (for a review, see (Andreasen, 2007) ). PAI-1-inactivating diketopiperazine derivatives Charlton et al., 1996; De Nanteuil et al., 2003; Folkes et al., 2001; Friederich et al., 1997; Wang et al., 2002) were by a variety of biochemical analyses shown to induce a stable, inactive PAI-1 conformation, which is different from other known PAI-1 conformations . A number of negatively charged, amphipathic organochemical compounds of diverse chemical structures were reported to inactivate the anti-proteolytic effects of PAI-1 Crandall et al., 2004; Egelund et al., 2001a; Gils et al., 2002; Munch et al., 1993; Urano et al., 1992) .
Available evidence, based on competition with monoclonal antibodies with known epitopes, sitedirected mutagenesis, and molecular modelling, suggests that these compounds bind in a hydrophobic pocket beneath α -helix D Egelund et al., 2001a; Gorlatova et al., 2007) . They rapidly induce PAI-1 substrate behaviour, followed by polymerisation (Egelund et al., 2001a; Pedersen et al., 2003) . Also, many monoclonal antibodies have been found to inactivate PAI-1, either by steric hindrance of the binding of the protease, by inducing substrate behaviour, or by rapidly converting PAI-1 to the latent state (for a review, see (Gils and Declerck, 2004) ).
We have chosen to explore the possibilities of deriving PAI-1-inactivating peptides from phage-displayed libraries. Our previous experience with such peptides suggests that they, in contrast to organochemical compounds, are likely to have specificities comparable to those of monoclonal antibodies, for instance having very different affinities to different conformations (Andersen et al., 2008; Dupont et al., 2006; Hansen et al., 2005; Sumbayev et al., 2005) . In contrast to organochemicals, they do not bind to serum albumin. In contrast to monoclonal antibodies, their small size allows for chemical modifications, for instance by insertion of non-natural amino acids. The first peptide designed to inhibit a serpin had a sequence corresponding to that of the part of the RCL which normally inserts in β-sheet A upon complex formation; such peptides occupy the place of the RCL in This article has not been copyedited and formatted. The final version may differ from this version. the sheet and induce substrate behaviour (Schulze et al., 1990) . From a phage-displayed peptide library, we previously isolated a peptide inhibiting the binding of protease-PAI-1 complexes to endocytosis receptors . In the present report, we describe the isolation of a peptide sequence, paionin-4, which accelerates the rate of conversion of PAI-1 to the latent state.
The possibility of inactivating PAI-1 by converting it to the latent state was originally suggested on the basis of investigations of inactivation of PAI-1 by the monoclonal anti-PAI-1 antibody MA33B8 (Verhamme et al., 1999) . MA33B8 binds preferentially to RCL-inserted forms of PAI-1. The theory originally proposed for the mechanism of action of MA33B8 was therefore that exposure of its epitope was coupled to at least a partial insertion of the RCL into β -sheet A. Since the conversion to the latent state is virtually irreversible, the observed antibody effect cannot be explained as a shifting of the equilibrium between active and latent forms towards the latent form. Therefore, the concept of a "prelatent" state was formulated. The prelatent state would be in equilibrium with the active state and would be more rapidly converted to the latent state than active PAI-1. Exposure of the MA33B8 epitope in the prelatent state would allow the antibody to stabilise this conformation, thereby shifting the equilibrium in favour of the pre-latent state and consequently accelerating latency transition (Verhamme et al., 1999) . By mapping the epitope of another antibody, H4B3, we recently provided evidence that the prelatent state involves the extraction of β -strand 1C from the β -sheet A, presumably coupled to the partial insertion of the RCL into β -sheet A (Dupont et al., 2006) . In the present report, we have substantiated the concept of the prelatent state. We show that another antibody, mAb-7, which also inactivates PAI-1, has an epitope overlapping with that of MA33B8, and, by the use of a peptidyl probe for latent PAI-1, surface plasmon resonance binding analysis, and fluorescence spectroscopy, demonstrate that binding of PAI-1 to the antibody is indeed associated with a fast conversion to the latent state.
Most importantly, we here report that the strategy of accelerating latency transition is also paionin-4 and the effect of the antibodies. First, while the antibodies convert PAI-1 to the latent state within seconds, the peptide merely causes an up to 3-fold acceleration of the rate of latency transition.
Second, the K D values for binding of mAb-7 to latent PAI-1 was here observed to be around 50 pM, while that of the peptide was around 300 nM. Third, the antibodies do not bind measurably to active PAI-1: By surface plasmon resonance binding analysis, we provided evidence that active PAI-1 is converted to the latent state during or very shortly after binding to mAb-7. In contrast, the difference in affinity of the peptide to the latent and active states was less than 10-fold. Fourth, although overlapping, the binding site for the peptide and the epitopes for the antibodies differed in important respects. Our data here are consistent with Trp88, Lys90, Asp91, Lys178, His231 being part of the epitope for mAb-7. Thus, the epitope include residues on 3 different secondary structural elements. In contrast, the residues mapped to the paionin-4 binding site were all, except Y81, localised to a single secondary structural element. This fact may underlie the much smaller difference in affinity between active and latent forms of PAI-1 for paionin-4 than for the antibodies. Nevertheless, the position of the residues in the paionin-4 binding site does vary between the three-dimensional structures of active and latent PAI-1 (Fig. 8) . In addition, it is remarkable that paionin-4 had a strongly reduced binding to both the human-hF-murine PAI-1 chimera and the murine-hF-human chimera. If paionin-4 binding had depended only on residues in α -helix D and the α -helix D-β-strand 2A loop, the human-hF-murine chimera should have bound paionin-4 as well as human PAI-1. It therefore seems that the conformation of the paioin-4 binding site also depends on residues in other secondary structural elements and that the effect of paionin-4 may indeed depend on the conformational changes of PAI-1.
Fifth, mAb-7 and paionin-4 differed with respect to their response to vitronectin: While the effect of mAb-7 is independent of the absence or presence of vitronectin , we showed here that vitronectin protects PAI-1 against paionin-4. Vitronectin has a very low affinity to latent PAI-1 (for a review, see (Wind et al., 2002) ). In this respect, paionin-4 resembles all the organochemical PAI-1 inactivators isolated to date (for a review, see (Andreasen, 2007) . Importantly, however, it is not known how fast PAI-1, after having been secreted from cells, reacts with vitronectin relative to its reaction with plasminogen activators. Indeed, the compound PAI-039 from which vitronectin protects PAI-1 in vitro, works well in vivo (Gorlatova et al., 2007) . Sixth, the observations concerning the This article has not been copyedited and formatted. The final version may differ from this version. differential reaction of stable PAI-1 14-1B and PAI-1 W177F to mAb-7 and paionin-4 are remarkable.
Whereas the stable PAI-1 variant 14-1B and PAI-1 W177F were both resistant to mAb-7, 14-1B seemed to react readily to paionin-4, whereas PAI-1 W177F had a somewhat reduced susceptibility. In the latent state, PAI-1 W177F mutant and wt PAI-1 demonstrated indistinguishable binding to both compounds, showing that W177 is not part of their binding sites. It is also clear that the residues mutated in 14-1B are distant from the binding for mAb-7 or paionin-4. But on the basis of the concept of the prelatent state, the decreased susceptibility of these mutants to mAb-7 is readily explained by the assumption that the prelatent state is less populated in the mutants than in wt. This notion is in agreement with the fact that both mutants have a reduced latency transition rate also in the absence of mAb-7. Thus, given the high susceptibility of 14-1B to paionin-4, comparable to that of wt, one would have to conclude that paionin-4 induces latency by a mechanism different from that of mAb-7. Taken together, all these differences suggest that in spite over the overlapping binding sites, the antibodies and paionin-4 accelerate latency transition by different mechanisms, the concept of the prelatent state being unable to explain the effect of paionin-4. Instead, we would like to suggest that paionin-4 induces a change facilitating loop insertion and acts by stabilising the transition state between active and latent PAI-1.
In spite of these differences, both paionin-4-D1D2 and mAb-7 bind as well to the uPA-PAI-1 complex as to latent PAI-1. This observation suggests a similar conformation of their common binding area in the two RCL-inserted forms.
Since our results here demonstrate that acceleration of latency transition can be achieved with a relatively small molecule, we believe our results represent an important step forward in providing strategies which may be employed for pharmacological inactivation of PAI-1. In the present case, with paionin-4 having 31 residues and an effect likely to depend on a fold stabilised by a complicated disulfide bridge pattern, the molecular recognition between the peptide and PAI-1 may indeed resemble that of an antibody. An important next step will be determination of the disulfide-bridge pattern of paionin-4. At the present stage, we have only used paionin-4 as a fusion protein with the 2 N-terminal domains of the phage coat protein g3p, D1 and D2. It is therefore important to state that there is no reason to believe that the paionin-4 peptide sequence does not fold as an independent This article has not been copyedited and formatted. The final version may differ from this version. . It therefore follows that also paionin-4, both when inserted in the phage and when fused to D1D2, has the disulphide bridge pattern determined by its sequence and giving the highest stability.
We would also like to draw the attention to the fact that the fusions proteins migrate as sharp peaks in gel filtration and non-reducing SDS-PAGE (Fig. 1) . If folding had been abnormal and heterogeneous, formation of oligomers would have been expected. An important next step will be to affinity-mature this peptide to achieve a higher affinity to PAI-1 and mapping of the PAI-1 binding area of paionin-4 by site-directed mutagenesis.
This article has not been copyedited and formatted. The final version may differ from this version. PAI-1 (110 nM), expressed from E. coli, was incubated at 37 ºC alone (dots) or in the presence of 10 µM P4-D1D2 fusion protein (crosses) or 10 µM D1D2 (triangles). At different time points, samples were added to and incubated in the wells of a Microtiter plate coated with mAb-6, for 30 minutes at 25 ºC. The amount of latent PAI-1 captured on the solid phase was subsequently detected using paionin-3 phage. The signals from wells without PAI-1 were subtracted.The experimental data points were fit to a mono-exponential approach to steady state (solid, stipled, and dashed lines, respectively).
The figure shows the result of one of four independent experiments. In the four experiments, the halflives were 57 ± 11 (no additions), 27 ±3 (with paionin-4-D1D2), and 49 ± 11 (with D1D2), corresponding to a statistically significant effect of paionin-4-D1D2 (p < 0.01), but not of D1D2. This article has not been copyedited and formatted. The final version may differ from this version. In order to determine the IC 50 values, PAI-1 was serially diluted at 37°C to concentrations between 0.4 and 400 nM and incubated for 20 min in the presence of mAb-7 in concentrations ranging from 0 to 80 nM. uPA was then added in portions of 25 µL to a final concentration of 10 nM.
After 5 min, the remaining uPA activity was determined and the specific inhibitory activity of PAI-1 determined from the PAI-1 concentration giving half-inhibition of the added uPA. The IC 50 values for the antibodies were determined from plots of the specific inhibitory activity of PAI-1 against the antibody concentration in the final assay mixture, as the antibody concentration reducing the specific inhibitory activity to 50%. Means, standard deviations, and numbers of determinations are indicated.
The following mutants had an IC 50 value less than 2-fold higher than that of wt: Y81A, H85A, Mapping of the epitope for mAb-7 by site-directed mutagenesis and surface plasmon resonance
The binding of PAI-1 wt and mutants to mAb-7 was analysed by surface plasmon resonance with a BIACORE T100 instrument, by injecting the PAI-1 variants, in the latent or uPA-complexed form, in concentrations between 0.25 and 500 nM over a BIACORE CM5 chip coated with with 200 RU of mAb-7.
The association (k 1 ) and dissociation (k -1 ) rate constants and the equilibrium dissociation constant (K D ) were determined by a global fit to the data according to a 1:1 binding model.
The following mutants showed no significant change in mAb-7 binding, as evaluated by BIACORE: Y81A, H85A, P87A, E92A, S94A, T96A, K143A, T144A, H145A, T146A, K147A, Y172A, N174A, W177F, D233, K325A, N331A, S333A. a In contrast to the other mutants, this one was applied to the BIACORE in the active form, as it is not possible to prepare a purely latent preparation of it due to the slow latency transition rate.
b Significantly different from the corresponding value for wt (p < 0.01).
